Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 2/20 | 0.43 |
| ▸ | CD22 | P20273 | 7/20 | 0.39 |
| ▸ | MAG | P20916 | 2/20 | 0.38 |
| ▸ | SIGLEC7 | Q9Y286 | 4/20 | 0.37 |
| ▸ | SELL | P14151 | 1/20 | 0.37 |
| ▸ | SELP | P16109 | 1/20 | 0.37 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.36 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22837962 | 0.92 | NANP (0.52) | NANPCD22MAG | |
| SCHEMBL12730475 | 0.89 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL14454528 | 0.89 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL12341443 | 0.89 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL12991357 | 0.86 | NANP (0.44) | NANPCD22MAG | |
| SCHEMBL23188763 | 0.85 | NANP (0.39) | NANPCD22MAG | |
| SCHEMBL14175641 | 0.82 | NANP (0.40) | NANPCD22 | |
| SCHEMBL13477004 | 0.82 | NANP (0.40) | NANPCD22 | |
| SCHEMBL15677307 | 0.81 | NANP (0.51) | NANPCD22MAG | |
| SCHEMBL29226087 | 0.81 | NANP (0.60) | NANPCD22MAGSIGLEC7SELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | BIOGENERIX AG (DE) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059780-A1 | BRANCHED PEG REMODELING AND GLYCOSYLATION OF GLUCAGON-LIKE PEPTIDE-1 [GLP-1] | GLP1R, GIPR, IAPP | NANP 866/4885CD22 407/4885MAG 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.